Compare AMP & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMP | TEVA |
|---|---|---|
| Founded | 1894 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6B | 39.9B |
| IPO Year | 2009 | N/A |
| Metric | AMP | TEVA |
|---|---|---|
| Price | $459.88 | $33.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $544.91 | $38.63 |
| AVG Volume (30 Days) | 566.0K | ★ 4.7M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 9.77 | N/A |
| EPS | ★ 9.68 | N/A |
| Revenue | ★ $18,911,000,000.00 | N/A |
| Revenue This Year | $1.79 | N/A |
| Revenue Next Year | $4.20 | $2.97 |
| P/E Ratio | $47.43 | ★ $28.19 |
| Revenue Growth | ★ 5.49 | N/A |
| 52 Week Low | $422.37 | $14.99 |
| 52 Week High | $550.18 | $37.35 |
| Indicator | AMP | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 48.38 |
| Support Level | $450.43 | $32.99 |
| Resistance Level | $474.78 | $35.37 |
| Average True Range (ATR) | 10.18 | 1.13 |
| MACD | 1.56 | -0.08 |
| Stochastic Oscillator | 86.88 | 46.48 |
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating profit from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.